SAB Biotherapeutics, Inc. - 10-Q Filing
SAB Biotherapeutics reports Q3 financial results including details on Series A and B preferred stock, warrant valuations, and clinical trial expense structures.
Tickers: $SABS
SAB Biotherapeutics reports Q3 financial results including details on Series A and B preferred stock, warrant valuations, and clinical trial expense structures.
Tickers: $SABS